ArticleFrontiers in cardiovascular medicine2025
Effect of folic acid and vitamin B12 plus rosuvastatin in the treatment of coronary heart disease combined with hyperlipidemia.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the effect of folic acid and vitamin B12 plus rosuvastatin in treating coronary heart disease (CHD) complicated with hyperlipidemia. Methods: One hundred CHD patients combined with hyperlipidemia admitted to our hospital from January 2022 to December 2023 were separated into study group as well as control group. The control group accepted rosuvastatin calcium tablets. The study group received rosuvastatin plus folic acid and vitamin B12. The cardiac function, blood lipid, plasma Hcy, folate and vitamin B12 levels, inflammation, clinical effect along with occurrence of adverse reactions were compared in 2 groups. Results: Compared to before therapy, LVEDD and LVESD levels were declined while LVEF level was elevated in 2 groups after therapy, TC, TG and LDL-C levels were declined while HDL-C level was elevated in 2 groups after therapy, plasma Hcy level was declined while folate and vitamin B12 levels were elevated in 2 groups after therapy, and IL-6, TNF-α along with CRP levels were declined in 2 groups after therapy. Compared to control group, the improvements of the above cardiac function indicators, blood lipid indexes, plasma Hcy, folate and vitamin B12 levels, serum inflammatory markers in the study group were more apparent, the total effective rate in the study group presented better. No difference was seen in the occurrence of adverse reactions between 2 groups. Conclusion: Folic acid and vitamin B12 plus rosuvastatin can effectively improve cardiac function, blood lipid, inflammatory response, and has high safety in treating CHD complicated with hyperlipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.